$MBOT
Microbot Medical Inc. Stock $mbot

$mbot Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045136 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.240M
YoY Change		33.33%
% of Gross Profit
Research & Development		$2.060M
YoY Change		27.79%
% of Gross Profit
Depreciation & Amortization		$23.00K
YoY Change		15.0%
% of Gross Profit
Operating Expenses		$2.060M
YoY Change		27.79%
Operating Profit		-$3.300M
YoY Change		29.72%
Interest Expense		$85.00K
YoY Change		-13.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$3.215M
YoY Change		31.22%
Income Tax
% Of Pretax Income
Net Earnings		-$3.215M
YoY Change		31.44%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.20
Diluted Earnings Per Share		-$0.20
COMMON SHARES
Basic Shares Outstanding	16.93M shares	16.50M shares
Diluted Shares Outstanding		16.47M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$4.338M
YoY Change		-46.77%
Cash & Equivalents		$479.0K
Short-Term Investments		$3.859M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$4.995M
YoY Change		-40.59%
LONG-TERM ASSETS
Property, Plant & Equipment		$99.00K
YoY Change		-46.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$213.0K
YoY Change		-55.72%
TOTAL ASSETS
Total Short-Term Assets		$4.995M
Total Long-Term Assets		$213.0K
Total Assets		$5.208M
YoY Change		-41.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$246.0K
YoY Change		3.36%
Accrued Expenses		$1.060M
YoY Change		1.24%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$1.371M
YoY Change		-8.05%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$29.00K
YoY Change		-27.5%
Total Long-Term Liabilities		$29.00K
YoY Change		-27.5%
TOTAL LIABILITIES
Total Short-Term Liabilities		$1.371M
Total Long-Term Liabilities		$29.00K
Total Liabilities		$1.400M
YoY Change		-8.5%
SHAREHOLDERS EQUITY
Retained Earnings		-$87.55M
YoY Change		14.68%
Common Stock		$91.36M
YoY Change		9.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$3.808M
YoY Change
Total Liabilities & Shareholders Equity		$5.208M
YoY Change		-41.4%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$3.215M
YoY Change		31.44%
Depreciation, Depletion And Amortization		$23.00K
YoY Change		15.0%
Cash From Operating Activities		-$2.759M
YoY Change		67.21%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$140.0K
YoY Change		-105.49%
Cash From Investing Activities		$140.0K
YoY Change		-105.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		633.0K
YoY Change		-495.62%
NET CHANGE
Cash From Operating Activities		-2.759M
Cash From Investing Activities		140.0K
Cash From Financing Activities		633.0K
Net Change In Cash		-1.986M
YoY Change		-54.66%
FREE CASH FLOW
Cash From Operating Activities		-$2.759M
Capital Expenditures		$0.00
Free Cash Flow		-$2.759M
YoY Change		64.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity File Number EntityFileNumber	000-19871
	dei	Entity Registrant Name EntityRegistrantName	MICROBOT MEDICAL INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3078125
	dei	Entity Address Address Line1 EntityAddressAddressLine1	288 Grove Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 388
	dei	Entity Address City Or Town EntityAddressCityOrTown	Braintree
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02184
	dei	City Area Code CityAreaCode	(781)
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	MBOT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4848000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2287000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9468000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000883975
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent		usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2468000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3859000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3917000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	48000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	49000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1335000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	609000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	4995000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7921000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	146000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	114000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	260000	usd
CY2023Q4	us-gaap	Assets Assets	8327000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	246000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	357000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	191000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2211000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1060000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1027000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1371000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3786000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1400000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3826000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16651433	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16651433	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11707317	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11707317	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	168000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	118000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	91192000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83884000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87552000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79501000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	3808000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4501000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5208000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1612000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Local Phone Number LocalPhoneNumber	875-3605
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16932341	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	479000	usd
CY2024Q3	us-gaap	Assets Assets	5208000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8327000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4646000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4594000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1240000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	932000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3549000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3193000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3300000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2544000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8195000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7787000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	85000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	98000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	144000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	201000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2446000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8051000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7586000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16471419	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16471419	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11707317	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11707317	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15129574	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15129574	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9653337	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9653337	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7289000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	412000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2853000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	349000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6558000	usd
CY2023Q1	MBOT	Issuance Of Common Stock Value Upon Exercise Of Warrants IssuanceOfCommonStockValueUponExerciseOfWarrants		usd
	MBOT	Increase Decrease In Legal Settlement And Legal Expenses Received In Cash IncreaseDecreaseInLegalSettlementAndLegalExpensesReceivedInCash		usd
	MBOT	Increase Decrease In Legal Settlement IncreaseDecreaseInLegalSettlement		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	MBOT	Accrued Executive Bonus Settled Through Grant Of Stockoption Awards AccruedExecutiveBonusSettledThroughGrantOfStockoptionAwards		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.01
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	152000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2060000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3215000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	336000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2446000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7358000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4501000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	529000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2397000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2397000	usd
CY2024Q1	MBOT	Issuance Of Common Stock Value Relating To Settlement Agreement IssuanceOfCommonStockValueRelatingToSettlementAgreement	1111000	usd
CY2024Q1	MBOT	Issuance Of Common Stock Value Relating To Settlement Agreement IssuanceOfCommonStockValueRelatingToSettlementAgreement	1111000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2371000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6167000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	331000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2022000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2022000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2465000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6055000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6055000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	283000	usd
CY2024Q3	MBOT	Issuance Of Common Stock Under Atthemarket Offering Program Net Of Issuance Costs IssuanceOfCommonStockUnderAtthemarketOfferingProgramNetOfIssuanceCosts	685000	usd
CY2024Q3	MBOT	Issuance Of Common Stock Under Atthemarket Offering Program Net Of Issuance Costs IssuanceOfCommonStockUnderAtthemarketOfferingProgramNetOfIssuanceCosts	685000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3215000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	3808000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	3808000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	333000	usd
CY2024Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	328000	usd
CY2024Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8051000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7586000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71000	usd
	MBOT	Interest Income And Unrealized Gains From Marketable Securities Net InterestIncomeAndUnrealizedGainsFromMarketableSecuritiesNet	2000	usd
	MBOT	Interest Income And Unrealized Gains From Marketable Securities Net InterestIncomeAndUnrealizedGainsFromMarketableSecuritiesNet	105000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1067000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1097000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	274000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-549000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-176000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-738000	usd
	MBOT	Increase Decrease In Legal Settlement And Legal Expenses Received In Cash IncreaseDecreaseInLegalSettlementAndLegalExpensesReceivedInCash	-1335000	usd
	MBOT	Increase Decrease In Legal Settlement IncreaseDecreaseInLegalSettlement	-1100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7136000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6712000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	5120000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	8379000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2680000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2039000	usd
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	2500000	usd
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	5389000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-984000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5104000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6558000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5104000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6558000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1990000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1138000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2517000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2519000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	527000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1381000	usd
	us-gaap	Interest Paid Net InterestPaidNet	168000	usd
	us-gaap	Interest Paid Net InterestPaidNet	100000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	37000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	20000	usd
	us-gaap	Stock Issued1 StockIssued1	1111000	usd
	MBOT	Accrued Executive Bonus Settled Through Grant Of Stockoption Awards AccruedExecutiveBonusSettledThroughGrantOfStockoptionAwards	76000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_z1cBzOl6IQLe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82A_zwLbwY2mVkq1">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Description of business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incorporated on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_c20240101__20240930_zv5N0WtjuE6i" title="Date of incorporation">August 2, 1988</span> in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Risk Factors</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated revenues from its operations. As of September 30, 2024, the Company had cash equivalents and a marketable securities balance of approximately $<span id="xdx_902_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20240930_zfA9mAsxPCT1" title="Cash equivalents and marketable securities">4,338</span>, excluding restricted cash. Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future, as well as to seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from government institutions. The Company will require additional capital and its ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">War in Israel</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2023, the State of Israel, where the Company’s operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to ongoing military operations and armed conflicts in the Gaza Strip. It continues to evolve and has since spread to northern Israel and threatens to spread to other Middle Eastern countries including Lebanon and Iran. These military operations and related activities are on-going as of the issuance date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has considered various ongoing risks relating to the military operation and related matters, including:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● That some of the Company’s Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● A slowdown in the number of international flights in and out of Israel; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Reduced workforce due to military service of some employees</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is closely monitoring how the military operation and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the filing date of the Quarterly Report on Form 10-Q of which these financial statements are a part, the Company has determined that there have not been any materially adverse effects on its business or operations, but it continues to monitor the situation, as any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support the Company’s clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Unaudited Interim Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim condensed financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim condensed consolidated financial statements should be read in conjunction with the latest audited financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for the nine-month period ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1988-08-02
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	4338000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zIj8sS9nPn2e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zR3SHY358rIf">Use of estimates</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	MBOT	Net Sales Royalty Percentage NetSalesRoyaltyPercentage	0.03	pure
CY2022Q4	MBOT	Gross Proceeds From Cash Fee Percentage GrossProceedsFromCashFeePercentage	0.070	pure
CY2022Q4	MBOT	Gross Proceeds From Management Fee Percentage GrossProceedsFromManagementFeePercentage	0.010	pure
CY2024Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	2154000	usd
CY2023Q4	MBOT	Settlement Agreement Liability SettlementAgreementLiability	2211000	usd
CY2023Q4	MBOT	Insurance Recoverable InsuranceRecoverable	1335000	usd
CY2023Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	1100000	usd
CY2023	us-gaap	Legal Fees LegalFees	235000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1111000	usd
CY2023Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2730000	usd
CY2023Q4	MBOT	Agent Fees And Other Offering Expenses AgentFeesAndOtherOfferingExpenses	333000	usd
CY2024Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000	usd
CY2024Q1	MBOT	Annual Bonus AnnualBonus	99000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-24-045136-index-headers.html	Edgar Link	pending
0001493152-24-045136-index.html	Edgar Link	pending
0001493152-24-045136.txt	Edgar Link	pending
0001493152-24-045136-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
mbot-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mbot-20240930_cal.xml	Edgar Link	unprocessable
mbot-20240930_def.xml	Edgar Link	unprocessable
mbot-20240930_lab.xml	Edgar Link	unprocessable
mbot-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBOT
Microbot Medical Inc. Stock $mbot

2024 Q4 Form 10-Q Financial Statement

#000149315224045136 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT Microbot Medical Inc. Stock $mbot

2024 Q4 Form 10-Q Financial Statement

#000149315224045136 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT
Microbot Medical Inc. Stock $mbot